SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
29. März 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release...
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
25. März 2024 10:15 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
23. Februar 2024 08:00 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08. Februar 2024 08:00 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics Announces Executive Leadership Change
02. Februar 2024 07:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
23. Januar 2024 17:58 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is...
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
02. Januar 2024 16:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human...
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
29. November 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG) SAB-142 directly and specifically targets multiple...
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
20. November 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a...
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
14. November 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditionsParticipating investors include Sessa Capital, BVF Partners, RTW...